<DOC>
	<DOC>NCT00275951</DOC>
	<brief_summary>The investigators have initial evidence that the combination of cetuximab and cisplatin-HDFL may further improve the efficacy of the cisplatin-HDFL combination chemotherapy.</brief_summary>
	<brief_title>Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer</brief_title>
	<detailed_description>The clinical efficacy (confirmed objective response rates, progression-free survival, overall survival), and treatment-related toxicities of this novel regimen will be examined as the first-line treatment in patients with nonresectable or recurrent/metastatic gastric cancer.</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1. Age 18 to 75 years 2. Histologically proven adenocarcinoma 3. At least one "measurable" lesion (by RECIST) 4. No prior chemotherapy for gastric cancer 5. WHO performance status â‰¦ 2 6. Adequate baseline organ functions 7. Fasting serum triglyceride level &gt; 70 mg/dL 8. Written informed consent 9. At least one month from gastrectomy 10. Availability of tumor sample for immunohistochemical or pharmacogenomic testing of EGFR 1. Concomitant anticancer biological agents, chemotherapy, or radiotherapy 2. CNS metastasis 3. Pregnancy, breastfeeding women and women of childbearing potential 4. Life expectancy less 3 months 5. Serious concomitant illness 6. Concurrent or prior second malignancy 7. Known hypersensitivity reaction to any of the components of study treatments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Combination</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Gastric cancer</keyword>
</DOC>